Now showing items 1-3 of 3

    • Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. 

      Yi, JS; Guidon, A; Sparks, S; Osborne, R; Juel, VC; Massey, JM; Sanders, DB; ... (9 authors) (J Autoimmun, 2014-08)
      Muscle specific tyrosine kinase myasthenia gravis (MuSK MG) is a form of autoimmune MG that predominantly affects women and has unique clinical features, including prominent bulbar weakness, muscle atrophy, and excellent ...
    • Eculizumab improves fatigue in refractory generalized myasthenia gravis. 

      Andersen, Henning; Mantegazza, Renato; Wang, Jing Jing; O'Brien, Fanny; Patra, Kaushik; Howard, James F; REGAIN Study Group (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2019-08)
      PURPOSE:To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders ...
    • 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. 

      Vissing, John; Jacob, Saiju; Fujita, Kenji P; O'Brien, Fanny; Howard, James F; REGAIN study group (Journal of neurology, 2020-07)
      <h4>Background</h4>The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory ...